CRIS Current Research Information System

De Lima, M., Kebriaei, P., Lanza, F., Cho, C., Popradi, G., Hemmer, M.T., et al. (2022). Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study. BLOOD, 140(Supplement 1), 6023-6025 [10.1182/blood-2022-160315].

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Lanza, F
Membro del Collaboration Group
;Zhang, F;
2022
2022
BLOOD
De Lima, M., Kebriaei, P., Lanza, F., Cho, C., Popradi, G., Hemmer, M.T., et al. (2022). Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study. BLOOD, 140(Supplement 1), 6023-6025 [10.1182/blood-2022-160315].
De Lima, MJG; Kebriaei, P; Lanza, F; Cho, C; Popradi, G; Hemmer, MT; Zhang, MJ; Zhang, F; Shah, R; Welch, V; Tikka, S; Vandendries, E; Stelljes, M; Ma...espandi
1.06 Abstract in rivista
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/924183
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 3
social impact